Investors had high hopes for VIVUS' (NASDAQ: VVUS) new anti-obesity drug Qsymia, but the drug debuted to lackluster sales -- and it's taking a toll on VIVUS' share price. Now, VIVUS is shifting its focus -- marketing not to the doctors who will be prescribing Qsymia, but directly to patients by offering a free trial. Does this shift represent a fundamentally different marketing approach for the company, and more importantly for investors, will it work? Health care analysts Max Macaluso and Brenton Flynn discuss this news in the following video.
Can VIVUS' marketing shift get its new obesity drug off the ground?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo
